BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20399994)

  • 1. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
    Li XN; Xu HR; Chen WL; Chu NN; Zhu JR
    Clin Ther; 2010 Mar; 32(3):575-87. PubMed ID: 20399994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
    Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
    Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
    Martin PD; Warwick MJ; Dane AL; Cantarini MV
    Clin Ther; 2003 Aug; 25(8):2215-24. PubMed ID: 14512129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
    Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
    Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
    Martin PD; Warwick MJ; Dane AL; Brindley C; Short T
    Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers.
    Li Y; Jiang X; Lan K; Jiang Q
    Eur J Drug Metab Pharmacokinet; 2009; 34(3-4):221-7. PubMed ID: 20166442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
    Liu YM; Pu HH; Liu GY; Jia JY; Weng LP; Xu RJ; Li GX; Wang W; Zhang MQ; Lu C; Yu C
    Clin Ther; 2010 Jul; 32(7):1396-407. PubMed ID: 20678686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
    Lee E; Ryan S; Birmingham B; Zalikowski J; March R; Ambrose H; Moore R; Lee C; Chen Y; Schneck D
    Clin Pharmacol Ther; 2005 Oct; 78(4):330-41. PubMed ID: 16198652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions.
    Trabelsi F; Bartůnek A; Vlavonou R; Navrátilová L; Dubé C; Tanguay M; Hauser T
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):741-50. PubMed ID: 22762855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
    Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
    Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
    Martin PD; Warwick MJ; Dane AL; Hill SJ; Giles PB; Phillips PJ; Lenz E
    Clin Ther; 2003 Nov; 25(11):2822-35. PubMed ID: 14693307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.
    Choi JH; Lee MG; Cho JY; Lee JE; Kim KH; Park K
    Clin Pharmacol Ther; 2008 Feb; 83(2):251-7. PubMed ID: 17568401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
    Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.
    Martin PD; Schneck DW; Dane AL; Warwick MJ
    Curr Med Res Opin; 2008 Apr; 24(4):1231-5. PubMed ID: 18355422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.
    Kiser JJ; Gerber JG; Predhomme JA; Wolfe P; Flynn DM; Hoody DW
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):570-8. PubMed ID: 18176327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
    Martin PD; Mitchell PD; Schneck DW
    Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.